Xencor Reports Fourth Quarter and Full Year 2025 Financial Results Read more about Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
Xencor Reports Third Quarter 2025 Financial Results Read more about Xencor Reports Third Quarter 2025 Financial Results
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read more about Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Xencor Reports Second Quarter 2025 Financial Results Read more about Xencor Reports Second Quarter 2025 Financial Results
Xencor Reports First Quarter 2025 Financial Results Read more about Xencor Reports First Quarter 2025 Financial Results
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease Read more about Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results Read more about Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
Xencor Reports Third Quarter 2024 Financial Results Read more about Xencor Reports Third Quarter 2024 Financial Results
Xencor Reports Second Quarter 2024 Financial Results Read more about Xencor Reports Second Quarter 2024 Financial Results
Xencor Reports First Quarter 2024 Financial Results Read more about Xencor Reports First Quarter 2024 Financial Results
